Growth Metrics

Lensar (LNSR) Preferred Stock Liabilities (2019)

Lensar (LNSR) reported Preferred Stock Liabilities of $36.4 million for Q4 2019.

Lensar (LNSR) has 1 years of Preferred Stock Liabilities data on file, last reported at $36.4 million in Q4 2019.

  • Quarterly Preferred Stock Liabilities changed N/A year-over-year to $36.4 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $36.4 million (changed N/A YoY) and the FY2019 annual result came in at $36.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities held at $36.4 million in Q4 2019 per LNSR's latest filing.
  • Across five years, Preferred Stock Liabilities topped out at $36.4 million in Q4 2019 and bottomed at $36.4 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Lensar 69.32 Mn 69.61 Mn 6.38 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 36.42 Mn